Could a heart drug shield blood vessels from reperfusion damage?
NCT ID NCT07192744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether rotigaptide, a drug that improves cell communication, can protect blood vessel function after a temporary blockage of blood flow (ischemia-reperfusion injury). Twelve healthy men received the drug or a placebo while their forearm blood flow was measured. The goal was to see if rotigaptide prevents the blood vessel damage that often occurs when blood flow is restored.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rotigaptide (ZP-123)
- What this could lead to
- If it works, this could point toward a treatment to protect blood vessels from damage after a heart attack or stroke.
- What could go wrong
- This is a very small, early study in healthy men, not patients. The results may not apply to real-world disease or lead to a therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHAEMIC HEART DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Edinburgh, 49 Little France Crescent
Edinburgh, EH16 4SB, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.